Medicines labeled for the same conditions
Alternatives to infliximab
3 other medicines are given the same way (intravenous) and in the same FDA class as infliximab or labeled mainly for the same use (rheumatoid arthritis); 1 is in its class, tumor necrosis factor blockers: golimumab; the others include 1 interleukin-6 receptor antagonist and 1 selective t cell costimulation modulator (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $12,890.32 per mL (Simponi 50 mg/0.5 mL pen injec) (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as infliximab?
Rheumatoid arthritis lists all 46 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Infliximabtumor necrosis factor blocker | this medicine | none listed | n/a | Yes | No current entry |
| Golimumabtumor necrosis factor blocker · same class | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | none listed | $12,890.32 per mL 50 mg/0.5 mL pen injec | Yes | No current entry |
| Tocilizumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $821.00 per mL 162 mg/0.9 mL autoinjct | Yes | No current entry |
| Abataceptselective t cell costimulation modulator | Rheumatoid arthritis | none listed | $1,469.23 per mL 125 mg/mL syringe | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Infliximab: the full record
- label, generics, price, shortages, recalls